Lilly pens AI-focused drug discovery deal with Atomwise
Executive Summary
Eli Lilly & Co. penned a deal with AI drug discovery firm Atomwise Inc. to support Lilly’s preclinical discovery efforts.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Services
-
Digital Health
- Artificial Intelligence
-
Biotechnology
-
Drug Discovery Tools
- ADMET
- Bioinformatics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice